Back to search
FDAFDA · Food and drugs·Recall number D-0506-2026

fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 1000 mcg/50mL (20 mcg per mL), well pharma of Houston, NDC 73702-203-65.

Published May 6, 2026 · Recall initiated: April 1, 2026

Summary

FDA records drug Class II recall D-0506-2026, published May 6, 2026 and initiated April 1, 2026. Recalling firm: Wells Pharma of Houston LLC; Status: Ongoing; Reported quantity: 150 syringes; Lot: Lot 022326203650432; Exp Date 06/25/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP deviations.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Wells Pharma of Houston LLC
Distributor
U.S. Nationwide.
Lot
Lot 022326203650432; Exp Date 06/25/2026
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 1000 mcg/50mL (20 mcg per mL), well pharma of Houston, NDC 73702-203-65. recalled?

Yes. FDA published recall D-0506-2026 on May 6, 2026. Reported hazard: cGMP deviations.

What should I do if I have this product?

Voluntary: Firm initiated · Letter